Nicholas Piramal (NPIL) is planning to sell its Deonar facility. The company plans to offer a Voluntary Retirement Scheme to its existing staff of around 180 people.
NPIL was formed by the triple merger with Sumitra Pharmaceuticals, Piramal Healthcare Boehringer Mannheim apart from the business of Roche earlier. The key therapeutic areas that the company focuses include antibiotics, cardiovasculars, nutritionals and central nervous system drugs.
The proposed sale of the Deonar facility is in line with the company’s continuous efforts to restructure its operations and bring about more efficiency in its functioning. The facility manufactures ointments and vitamins that are anyway being manufactured at the company’s other facilities.
Since Deonar is within Mumbai itself the company can hope to get a good price for its real estate and deploy the money towards partly paying of the VRS of its workers and using the balance cash for shoring its pharmaceutical business.
It would also reduce the cost of operations for the company since Mumbai is one of the costliest places to run a manufacturing operation.
However the sale of Deonar facility would only be one of the number of moves to restructure the company. The others include the sale of the bulk drug unit and the sale of the stake in Gujarat Glass.
The company has been rated as a 'buy' by most analysts primarily due to the company’s restructuring where both the bulk drugs as well the non-pharma activities would be hived off, the management’s proactive approach in forming co-marketing alliances with multinationals and the expected dilution of price control which would bring down the share of revenues from products under price control for NPIL to less than 42%.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407